Latest From PolyPeptide Group
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PolyPeptide Group
- Senior Management
- Contact Info
Phone: 40 366 200
P.O. Box 30089 Limhamn, 200 61
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.